Quest’s fragile X test approved in New York
This article was originally published in Clinica
Quest Diagnostics’ XSense test, which is used to screen for fragile X syndrome, has been approved by New York State’s department of health. The firm launched it in the rest of the US in February; however, New York has an independent regulatory review process for lab-developed tests. Fragile X syndrome is an inherited form of mental retardation caused by mutations in the FMR1 gene. XSense can be used to screen newborns or women of childbearing age, to identify carriers. Quest hopes that its test will replace the previous gold standard, the Southern blot, which is “labour intensive” and can take up to two weeks to produce results (www.clinica.co.uk, 14 April 2010). XSense, which uses triplet-primed PCR with capillary electrophoresis technology, takes around a week, Quest (Madison, New Jersey) said.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.